European Journal of Nuclear Medicine and Molecular Imaging最新文献

{"title":"Sedation-free pediatric [¹⁸F]FDG imaging on totalbody PET/CT with the assistance of artificial intelligence.","authors":"Xiang Zhou, Song Xue, Lianghua Li, Robert Seifert, Shunjie Dong, Ruohua Chen, Gang Huang, Axel Rominger, Jianjun Liu, Kuangyu Shi","doi":"10.1007/s00259-024-06818-3","DOIUrl":"10.1007/s00259-024-06818-3","url":null,"abstract":"<p><strong>Purpose: </strong>While sedation is routinely used in pediatric PET examinations to preserve diagnostic quality, it may result in side effects and may affect the radiotracer's biodistribution. This study aims to investigate the feasibility of sedation-free pediatric PET imaging using ultra-fast total-body (TB) PET scanners and deep learning (DL)-based attenuation and scatter correction (ASC).</p><p><strong>Methods: </strong>This retrospective study included TB PET (uExplorer) imaging of 35 sedated pediatric patients under four years old to determine the minimum effective scanning time. A DL-based ASC method was applied to enhance PET quantification. Both quantitative and qualitative assessments were conducted to evaluate the image quality of ultra-fast DL-ASC PET. Five non-sedated pediatric patients were subsequently used to validate the proposed approach.</p><p><strong>Results: </strong>Comparisons between standard 300-second and ultra-fast 15-second imaging, CT-ASC and DL-ASC ultra-fast 15-second images, as well as DL-ASC ultra-fast 15-second images in non-sedated and sedated patients, showed no significant differences in qualitative scoring, lesion detectability, and quantitative Standard Uptake Value (SUV) (P = ns).</p><p><strong>Conclusions: </strong>This study demonstrates that pediatric PET imaging can be effectively performed without sedation by combining ultra-fast imaging techniques with a DL-based ASC. This advancement in sedation-free ultra-fast PET imaging holds potential for broader clinical adoption.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":null,"pages":null},"PeriodicalIF":8.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141491403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multi-modality deep learning-based [⁶⁸Ga]Ga-DOTA-FAPI-04 PET polar map generation: potential value in detecting reactive fibrosis after myocardial infarction.","authors":"Xiaoya Qiao, Hanzhong Wang, Hongping Meng, Yun Xi, David Dagan Feng, Biao Li, Xiaoxiang Yan, Min Zhang, Qiu Huang","doi":"10.1007/s00259-024-06850-3","DOIUrl":"10.1007/s00259-024-06850-3","url":null,"abstract":"<p><strong>Purpose: </strong>Generating polar map (PM) from [⁶⁸Ga]Ga-DOTA-FAPI-04 PET images is challenging and inaccurate using existing automatic methods that rely on the myocardial anatomical integrity in PET images. This study aims to enhance the accuracy of PM generated from [⁶⁸Ga]Ga-DOTA-FAPI-04 PET images and explore the potential value of PM in detecting reactive fibrosis after myocardial infarction and assessing its relationship with cardiac function.</p><p><strong>Methods: </strong>We proposed a deep-learning-based method that fuses multi-modality images to compensate for the cardiac structural information lost in [⁶⁸Ga]Ga-DOTA-FAPI-04 PET images and accurately generated PMs. We collected 133 pairs of [⁶⁸Ga]Ga-DOTA-FAPI-04 PET/MR images from 87 ST-segment elevated myocardial infarction patients for training and evaluation purposes. Twenty-six patients were selected for longitudinal analysis, further examining the clinical value of PM-related imaging parameters.</p><p><strong>Results: </strong>The quantitative comparison demonstrated that our method was comparable with the manual method and surpassed the commercially available software-PMOD in terms of accuracy in generating PMs for [⁶⁸Ga]Ga-DOTA-FAPI-04 PET images. Clinical analysis revealed the effectiveness of [⁶⁸Ga]Ga-DOTA-FAPI-04 PET PM in detecting reactive myocardial fibrosis. Significant correlations were demonstrated between the difference of baseline PM FAPI% and PM LGE%, and the change in cardiac function parameters (all p < 0.001), including LVESV% (r = 0.697), LVEDV% (r = 0.621) and LVEF% (r = -0.607).</p><p><strong>Conclusion: </strong>The [⁶⁸Ga]Ga-DOTA-FAPI-04 PET PMs generated by our method are comparable to manually generated and sufficient for clinical use. The PMs generated by our method have potential value in detecting reactive fibrosis after myocardial infarction and were associated with cardiac function, suggesting the possibility of enhancing clinical diagnostic practices.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov (NCT04723953). Registered 26 January 2021.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":null,"pages":null},"PeriodicalIF":8.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141765811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with ⁸⁹Zr-labelled CI-8993.","authors":"Ingrid Julienne Georgette Burvenich, Christian Werner Wichmann, Alexander Franklin McDonald, Nancy Guo, Angela Rigopoulos, Nhi Huynh, Mary Vail, Stacey Allen, Graeme Joseph O'Keefe, Fiona Elizabeth Scott, Raul Soikes, Steven Angelides, Reinhard von Roemeling, Andrew Mark Scott, Ingrid Julienne, Georgette Burvenich","doi":"10.1007/s00259-024-06869-6","DOIUrl":"10.1007/s00259-024-06869-6","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":null,"pages":null},"PeriodicalIF":8.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11527942/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142055261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IE-CycleGAN: improved cycle consistent adversarial network for unpaired PET image enhancement.","authors":"Jianan Cui, Yi Luo, Donghe Chen, Kuangyu Shi, Xinhui Su, Huafeng Liu","doi":"10.1007/s00259-024-06823-6","DOIUrl":"10.1007/s00259-024-06823-6","url":null,"abstract":"<p><strong>Purpose: </strong>Technological advances in instruments have greatly promoted the development of positron emission tomography (PET) scanners. State-of-the-art PET scanners such as uEXPLORER can collect PET images of significantly higher quality. However, these scanners are not currently available in most local hospitals due to the high cost of manufacturing and maintenance. Our study aims to convert low-quality PET images acquired by common PET scanners into images of comparable quality to those obtained by state-of-the-art scanners without the need for paired low- and high-quality PET images.</p><p><strong>Methods: </strong>In this paper, we proposed an improved CycleGAN (IE-CycleGAN) model for unpaired PET image enhancement. The proposed method is based on CycleGAN, and the correlation coefficient loss and patient-specific prior loss were added to constrain the structure of the generated images. Furthermore, we defined a normalX-to-advanced training strategy to enhance the generalization ability of the network. The proposed method was validated on unpaired uEXPLORER datasets and Biograph Vision local hospital datasets.</p><p><strong>Results: </strong>For the uEXPLORER dataset, the proposed method achieved better results than non-local mean filtering (NLM), block-matching and 3D filtering (BM3D), and deep image prior (DIP), which are comparable to Unet (supervised) and CycleGAN (supervised). For the Biograph Vision local hospital datasets, the proposed method achieved higher contrast-to-noise ratios (CNR) and tumor-to-background SUVmax ratios (TBR) than NLM, BM3D, and DIP. In addition, the proposed method showed higher contrast, SUV_max, and TBR than Unet (supervised) and CycleGAN (supervised) when applied to images from different scanners.</p><p><strong>Conclusion: </strong>The proposed unpaired PET image enhancement method outperforms NLM, BM3D, and DIP. Moreover, it performs better than the Unet (supervised) and CycleGAN (supervised) when implemented on local hospital datasets, which demonstrates its excellent generalization ability.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":null,"pages":null},"PeriodicalIF":8.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141747758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Using machine learning to improve the diagnostic accuracy of the modified Duke/ESC 2015 criteria in patients with suspected prosthetic valve endocarditis - a proof of concept study.","authors":"D Ten Hove, R H J A Slart, A W J M Glaudemans, D F Postma, A Gomes, L E Swart, W Tanis, P P van Geel, G Mecozzi, R P J Budde, K Mouridsen, B Sinha","doi":"10.1007/s00259-024-06774-y","DOIUrl":"10.1007/s00259-024-06774-y","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Prosthetic valve endocarditis (PVE) is a serious complication of prosthetic valve implantation, with an estimated yearly incidence of at least 0.4-1.0%. The Duke criteria and subsequent modifications have been developed as a diagnostic framework for infective endocarditis (IE) in clinical studies. However, their sensitivity and specificity are limited, especially for PVE. Furthermore, their most recent versions (ESC2015 and ESC2023) include advanced imaging modalities, e.g., cardiac CTA and [&lt;sup&gt;18&lt;/sup&gt;F]FDG PET/CT as major criteria. However, despite these significant changes, the weighing system using major and minor criteria has remained unchanged. This may have introduced bias to the diagnostic set of criteria. Here, we aimed to evaluate and improve the predictive value of the modified Duke/ESC 2015 (MDE2015) criteria by using machine learning algorithms.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;In this proof-of-concept study, we used data of a well-defined retrospective multicentre cohort of 160 patients evaluated for suspected PVE. Four machine learning algorithms were compared to the prediction of the diagnosis according to the MDE2015 criteria: Lasso logistic regression, decision tree with gradient boosting (XGBoost), decision tree without gradient boosting, and a model combining predictions of these (ensemble learning). All models used the same features that also constitute the MDE2015 criteria. The final diagnosis of PVE, based on endocarditis team consensus using all available clinical information, including surgical findings whenever performed, and with at least 1 year follow up, was used as the composite gold standard.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The diagnostic performance of the MDE2015 criteria varied depending on how the category of 'possible' PVE cases were handled. Considering these cases as positive for PVE, sensitivity and specificity were 0.96 and 0.60, respectively. Whereas treating these cases as negative, sensitivity and specificity were 0.74 and 0.98, respectively. Combining the approaches of considering possible endocarditis as positive and as negative for ROC-analysis resulted in an excellent AUC of 0.917. For the machine learning models, the sensitivity and specificity were as follows: logistic regression, 0.92 and 0.85; XGBoost, 0.90 and 0.85; decision trees, 0.88 and 0.86; and ensemble learning, 0.91 and 0.85, respectively. The resulting AUCs were, in the same order: 0.938, 0.937, 0.930, and 0.941, respectively.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Discussion: &lt;/strong&gt;In this proof-of-concept study, machine learning algorithms achieved improved diagnostic performance compared to the major/minor weighing system as used in the MDE2015 criteria. Moreover, these models provide quantifiable certainty levels of the diagnosis, potentially enhancing interpretability for clinicians. Additionally, they allow for easy incorporation of new and/or refined criteria, such as the individual weight of advanced imaging modalit","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":null,"pages":null},"PeriodicalIF":8.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11527948/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141431686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"⁶⁸Ga-Trivehexin PET/CT: a promising novel tracer for primary hyperparathyroidism.","authors":"Serkan Kuyumcu, Dilara Denizmen, Duygu Has-Simsek, Arzu Poyanli, Ayşe Kubat Uzum, Fikret Buyukkaya, Emine Goknur Isik, Semen Onder, Nihat Aksakal, Zeynep Gozde Ozkan, Yasemin Sanli","doi":"10.1007/s00259-024-06846-z","DOIUrl":"10.1007/s00259-024-06846-z","url":null,"abstract":"<p><strong>Introduction: </strong>This study aims to assess ⁶⁸Ga-Trivehexin PET/CT for detecting hyperfunctioning parathyroid tissue in comparison to [^99mTc]Tc-MIBI scintigraphy-SPECT/CT (MIBI scan) in patients with primary hyperparathyroidism (PHPT).</p><p><strong>Methods: </strong>The cohort comprised 13 patients diagnosed with PHPT based on biochemical analyses, including serum calcium, phosphorus, and parathyroid hormone (PTH) levels. Each participant underwent cervical ultrasonography, MIBI scan, and ⁶⁸Ga-Trivehexin PET/CT imaging. Complementary 4D-CT and [¹⁸F]fluorocholine PET/CT were conducted in 7 patients. Ten lesions of 7 patients underwent PTH wash-out (WO) procedure. ⁶⁸Ga-Trivehexin PET/CT findings were compared with other modalities and PTH-WO results.</p><p><strong>Results: </strong>Ten patients had sporadic PHPT, while 3 were diagnosed with MEN-1 syndrome-associated PHPT. One patient did not have any identifiable parathyroid lesion across the imaging modalities. On a patient-based analysis, MIBI scan and ⁶⁸Ga-Trivehexin PET/CT identified parathyroid lesions in 10 and 11 patients, respectively. However, ⁶⁸Ga-Trivehexin PET/CT detected 7 additional parathyroid lesions that were negative on the MIBI scan. Consequently, 17 lesions were identified and confirmed as hyperfunctioning parathyroid tissue through imaging, PTH-WO, or a combination of both modalities. In lesion-based evaluation, ⁶⁸Ga-Trivehexin identified 16 lesions compared to 10 by MIBI scan, resulting in a detection rate of 94.1% and 58.8%, respectively. Notably, in three patients who underwent [¹⁸F]fluorocholine PET/CT, no lesions were detected; yet ⁶⁸Ga-Trivehexin PET/CT successfully identified parathyroid lesions in two of these patients.</p><p><strong>Conclusion: </strong>Our study provides the first evidence that ⁶⁸Ga-Trivehexin PET/CT can effectively identify hyperfunctioning parathyroid tissue with a high detection rate warranting further investigations to comprehensively explore its potential in PHPT management.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":null,"pages":null},"PeriodicalIF":8.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11527967/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141723306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of the tolerability of ¹⁶¹Tb- and ¹⁷⁷Lu-labeled somatostatin analogues in the preclinical setting.","authors":"Sarah D Busslinger, Ana Katrina Mapanao, Kristel Kegler, Peter Bernhardt, Fabienne Flühmann, Julia Fricke, Jan Rijn Zeevaart, Ulli Köster, Nicholas P van der Meulen, Roger Schibli, Cristina Müller","doi":"10.1007/s00259-024-06827-2","DOIUrl":"10.1007/s00259-024-06827-2","url":null,"abstract":"<p><strong>Purpose: </strong>[¹⁷⁷Lu]Lu-DOTATATE is an established somatostatin receptor (SSTR) agonist for the treatment of metastasized neuroendocrine neoplasms, while the SSTR antagonist [¹⁷⁷Lu]Lu-DOTA-LM3 has only scarcely been employed in clinics. Impressive preclinical data obtained with [¹⁶¹Tb]Tb-DOTA-LM3 in tumor-bearing mice indicated the potential of terbium-161 as an alternative to lutetium-177. The aim of the present study was to compare the tolerability of ¹⁶¹Tb- and ¹⁷⁷Lu-based DOTA-LM3 and DOTATATE in immunocompetent mice.</p><p><strong>Methods: </strong>Dosimetry calculations were performed based on biodistribution data of the radiopeptides in immunocompetent mice. Treatment-related effects on blood cell counts were assessed on Days 10, 28 and 56 after application of [¹⁶¹Tb]Tb-DOTA-LM3 or [¹⁶¹Tb]Tb-DOTATATE at 20 MBq per mouse. These radiopeptides were also applied at 100 MBq per mouse and the effects compared to those observed after application of the ¹⁷⁷Lu-labeled counterparts. Bone marrow smears, blood plasma parameters and organ histology were assessed at the end of the study.</p><p><strong>Results: </strong>The absorbed organ dose was commonly higher for the SSTR antagonist than for the SSTR agonist and for terbium-161 over lutetium-177. Application of a therapeutic activity level of 20 MBq [¹⁶¹Tb]Tb-DOTA-LM3 or [¹⁶¹Tb]Tb-DOTATATE was well tolerated without major hematological changes. The injection of 100 MBq of the ¹⁶¹Tb- and ¹⁷⁷Lu-based somatostatin analogues affected the blood cell counts, however. The lymphocytes were 40-50% lower in treated mice compared to the untreated controls on Day 10 irrespective of the radionuclide employed. At the same timepoint, thrombocyte and erythrocyte counts were 30-50% and 6-12% lower, respectively, after administration of the SSTR antagonist (p < 0.05) while changes were less pronounced in mice injected with the SSTR agonist. All blood cell counts were in the normal range on Day 56. Histological analyses revealed minimal abnormalities in the kidneys, liver and spleen of treated mice. No correlation was observed between the organ dose and frequency of the occurrence of abnormalities.</p><p><strong>Conclusion: </strong>Hematologic changes were more pronounced in mice treated with the SSTR antagonist than in those treated with the SSTR agonist. Despite the increased absorbed dose delivered by terbium-161 over lutetium-177, [¹⁶¹Tb]Tb-DOTA-LM3 and [¹⁶¹Tb]Tb-DOTATATE should be safe at activity levels that are recommended for their respective ¹⁷⁷Lu-based analogues.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":null,"pages":null},"PeriodicalIF":8.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11527941/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141751435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-in-human evaluation of 6-bromo-7-[¹¹C]methylpurine, a PET tracer for assessing the function of multidrug resistance-associated proteins in different tissues.","authors":"Severin Mairinger, Matthias Jackwerth, Zacharias Chalampalakis, Ivo Rausch, Maria Weber, Michael Wölfl-Duchek, Lena Pracher, Lukas Nics, Jens Pahnke, Werner Langsteger, Marcus Hacker, Markus Zeitlinger, Oliver Langer","doi":"10.1007/s00259-024-06851-2","DOIUrl":"10.1007/s00259-024-06851-2","url":null,"abstract":"<p><strong>Purpose: </strong>Multidrug resistance-associated protein 1 (MRP1) is a transport protein with a widespread tissue distribution, which has been implicated in the pathophysiology of Alzheimer's and chronic respiratory disease. PET with 6-bromo-7-[¹¹C]methylpurine ([¹¹C]BMP) has been used to measure MRP1 function in rodents. In this study, [¹¹C]BMP was for the first time characterised in humans to assess the function of MRP1 and other MRP subtypes in different tissues.</p><p><strong>Methods: </strong>Thirteen healthy volunteers (7 men, 6 women) underwent dynamic whole-body PET scans on a long axial field-of-view (LAFOV) PET/CT system after intravenous injection of [¹¹C]BMP. Three subjects of each sex were scanned a second time to assess reproducibility. Volumes of interest were outlined for MRP-expressing tissues (cerebral cortex, cerebellum, choroid plexus, retina, lungs, myocardium, kidneys, and liver). From the time-activity curves, the elimination rate constant (k_E, h^- 1) was derived as a parameter for tissue MRP function and its test-retest variability (TRTV, %) was calculated. Radiation dosimetry was calculated using the Medical Internal Radiation Dose (MIRD) methodology.</p><p><strong>Results: </strong>Mean k_E and corresponding TRTV values were: cerebral cortex: 0.055 ± 0.010 h^- 1 (- 4 ± 24%), cerebellum: 0.033 ± 0.009 h^- 1 (1 ± 39%), choroid plexus: 0.292 ± 0.059 h^- 1 (0.1 ± 16%), retina: 0.234 ± 0.045 h^- 1 (30 ± 38%), lungs: 0.875 ± 0.095 h^- 1 (- 3 ± 11%), myocardium: 0.641 ± 0.105 h^- 1 (11 ± 25%), kidneys: 1.378 ± 0.266 h^- 1 (14 ± 16%), and liver: 0.685 ± 0.072 h^- 1 (7 ± 9%). Significant sex differences were found for k_E in the cerebellum, lungs and kidneys. Effective dose was 4.67 ± 0.18 µSv/MBq for men and 4.55 ± 0.18 µSv/MBq for women.</p><p><strong>Conclusion: </strong>LAFOV PET/CT with [¹¹C]BMP potentially allows for simultaneous assessment of MRP function in multiple human tissues. Mean TRTV of k_E in different tissues was in an acceptable range, except for the retina. The radiation dosimetry of [¹¹C]BMP was in the typical range of ¹¹C-tracers. LAFOV PET/CT holds great potential to assess at a whole-body, multi-tissue level molecular targets relevant for drug disposition in humans.</p><p><strong>Trial registration: </strong>EudraCT 2021-006348-29. Registered 15 December 2021.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":null,"pages":null},"PeriodicalIF":8.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11527933/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141765810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the efficacy of [¹⁷⁷Lu]Lu-FAP-2286 in combination therapy for metastatic breast cancer.","authors":"Serkan Kuyumcu, Duygu Has-Şimşek","doi":"10.1007/s00259-024-06864-x","DOIUrl":"10.1007/s00259-024-06864-x","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":null,"pages":null},"PeriodicalIF":8.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141874511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating [²²⁵Ac]Ac-FAPI-46 for the treatment of soft-tissue sarcoma in mice.","authors":"Marco F Taddio, Suraj Doshi, Marwan Masri, Pauline Jeanjean, Firas Hikmat, Alana Gerlach, Lea Nyiranshuti, Ethan W Rosser, Dorthe Schaue, Elie Besserer-Offroy, Giuseppe Carlucci, Caius G Radu, Johannes Czernin, Katharina Lückerath, Christine E Mona","doi":"10.1007/s00259-024-06809-4","DOIUrl":"10.1007/s00259-024-06809-4","url":null,"abstract":"<p><strong>Purpose: </strong>Fibroblast Activation Protein (FAP) is an emerging theranostic target that is highly expressed on cancer-associated fibroblasts and on certain tumor cells including sarcoma. We investigated the anti-tumor efficacy of [²²⁵Ac]Ac-FAPI-46 as monotherapy or in combination with immune checkpoint blockade (ICB) in immunocompetent murine models of sarcoma sensitive or resistant to ICB.</p><p><strong>Methods: </strong>[⁶⁸Ga]Ga- and [²²⁵Ac]Ac-FAPI-46 were tested in subcutaneous FAP+ FSA fibrosarcoma bearing C3H/Sed/Kam mice. The efficacy of up to three cycles of 60 kBq [²²⁵Ac]Ac-FAPI-46 was evaluated as monotherapy and in combination with an anti-PD-1 antibody. Efficacy of [²²⁵Ac]Ac-FAPI-46 and/or ICB was further compared in FAP-overexpressing FSA (FSA-F) tumors that were sensitive to ICB or rendered ICB-resistant by tumor-induction in the presence of Abatacept.</p><p><strong>Results: </strong>[²²⁵Ac]Ac-FAPI-46 was well tolerated up to 3 × 60 kBq but had minimal effect on FSA tumor growth. The combination of three cycles [²²⁵Ac]Ac-FAPI-46 and ICB resulted in growth delay in 55% of mice (6/11) and partial tumor regression in 18% (2/11) of mice. In FSA-F tumors with FAP overexpression, both [²²⁵Ac]Ac-FAPI-46 and ICB were effective without additional benefits from the combination. In locally immunosuppressed and ICB resistant FAP-F tumors, however, [²²⁵Ac]Ac-FAPI-46 restored responsiveness to ICB, resulting in significant tumor regression and tumor-free survival of 56% of mice in the combination group up to 60 days post treatment.</p><p><strong>Conclusion: </strong>[²²⁵Ac]Ac-FAPI-46 efficacy is correlated with tumoral FAP expression levels and can restore responsiveness to PD-1 ICB. These data illustrate that careful patient selection based on target expression and rationally designed combination therapies are critically important to maximize the therapeutic impact of FAP-targeting radioligands.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":null,"pages":null},"PeriodicalIF":8.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11527918/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141616173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}